Related Experiment Videos
Platelets and antiplatelet therapy in patients with diabetes mellitus
Heidar Arjomand1, Bassam Roukoz, Satish K Surabhi
1Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA.
Insights
Diabetic patients have hyperreactive platelets, increasing ischemic heart disease risk. Antiplatelet agents effectively reduce these risks, with glycoprotein IIb/IIIa inhibitors improving survival during percutaneous coronary intervention.
Area of Science:
- Cardiology
- Diabetology
- Hematology
Background:
- Atherosclerotic heart disease is the primary cause of mortality in diabetes mellitus.
- Platelets are crucial in ischemic heart disease manifestations.
- Diabetic patients exhibit hyperreactive platelets, leading to increased adhesion, aggregation, and thrombin generation.
Purpose of the Study:
- To review the role of platelets in diabetes-related cardiovascular complications.
- To evaluate the efficacy of antiplatelet agents in diabetic patients.
- To assess the impact of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Main Methods:
- Literature review of studies on diabetes, platelets, and cardiovascular events.
- Analysis of clinical trial data on antiplatelet therapies.
- Examination of outcomes for diabetic patients undergoing percutaneous coronary intervention.
Main Results:
- Diabetic patients possess hyperreactive platelets, contributing to higher ischemic event rates.
- Antiplatelet agents like aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors significantly reduce recurrent ischemic events.
- Glycoprotein IIb/IIIa inhibitors demonstrated a reduction in mortality for diabetic patients during percutaneous coronary intervention.
Conclusions:
- Platelet hyperreactivity is a key factor in cardiovascular mortality in diabetes.
- Antiplatelet therapy is essential for managing ischemic heart disease in diabetic populations.
- Glycoprotein IIb/IIIa inhibitors offer survival benefits in diabetic patients undergoing percutaneous coronary intervention.
Abstract:
Atherosclerotic heart disease is the leading cause of death in patients with diabetes mellitus. Platelets play a major role in the clinical manifestations of ischemic heart disease. Diabetic patients have hyperreactive platelets with exaggerated adhesion, aggregation and thrombin generation. Antiplatelet agents, including aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors, have shown significant efficacy in reducing recurrent ischemic events in patients with diabetes. Treatment with glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention reduces mortality in diabetic patients.